TAK, US8740602052

Takeda Pharmaceutical stock gained 1.63 percent as results near

Published on 10/07/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda Pharmaceutical stock rose to USD 18.10 on October 6, 2026, while Q1 EPS reached USD 0.95. Q2 results are scheduled for October 29.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical stock (ISIN US8740602052) was last at USD 18.10 on the NYSE on October 6, 2026 at 4:00 p.m. ET, up 1.63 percent from the prior close. The next reported checkpoint is scheduled for October 29, 2026, when Takeda is set to publish its Q2 2027 results.

Q1 earnings beat expectations

MarketBeat reported on October 3, 2026 that Takeda's Q1 2027 earnings reached USD 0.95 per share, compared with a USD 0.41 consensus estimate, a USD 0.54 beat. Quarterly revenue came to USD 7.50 billion against USD 7.13 billion expected.

The result gives the stock a concrete earnings cushion ahead of the next report. Revenue exceeded the consensus by USD 0.37 billion, while the per-share beat was larger than the estimate itself, making earnings delivery the central near-term measure for investors.

Guidance sets the next test

According to MarketBeat, Takeda's fiscal 2026 guidance was listed at USD 3.009 EPS and USD 29.6 billion in revenue, versus consensus figures of USD 1.570 EPS and USD 29.0 billion in revenue. The source identifies the guidance update with the July 30, 2026 results.

That combination puts the October report in a sharper context: Q1 beat estimates, but the market will measure whether the earnings trajectory supports the full-year outlook. Takeda's portfolio spans gastrointestinal medicines, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, according to the company's investor information page.

Shares remain below yearly high

The October 6 price of USD 18.10 sits 5.24 percent below the 52-week high of USD 19.10 and 39.34 percent above the 52-week low of USD 12.99. The same session recorded a low of USD 17.95 and a high of USD 18.18, with volume of 3,097,362 shares.

The market capitalization stood at USD 57.6 billion on October 6, 2026. MarketBeat said on October 3, 2026 that Zacks Research moved its rating from strong buy to hold. That change adds a more cautious counterpoint to the latest earnings beat and keeps the October reporting date important for the stock's next valuation signal.

October 29 report date

Takeda Pharmaceutical is scheduled to report Q2 2027 results on October 29, 2026 before the market opens. The date and the expected USD 0.15 consensus EPS are listed by MarketBeat.